Department of Medicine, Division of Infectious Disease, University of California, San Diego, La Jolla, CA 92093-0676, USA.
Antiviral Res. 2009 Dec;84(3):254-9. doi: 10.1016/j.antiviral.2009.09.012. Epub 2009 Oct 1.
Our previous studies showed that esterification of 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine (HPMPA) or 1-(S)-[3-hydroxy-2-(phosphonomethoxy)-propyl]cytosine (HPMPC) with alkoxyalkyl groups such as hexadecyloxypropyl (HDP) or octadecyloxyethyl (ODE) resulted in large increases in antiviral activity and oral bioavailability. The HDP and ODE esters of HPMPA were shown to be active in cells infected with human immunodeficiency virus, type 1 (HIV-1), while HPMPA itself was virtually inactive. To explore this approach in greater detail, we synthesized four new compounds in this series, the ODE esters of 9-(S)-[3-hydroxy-2-(phosphonomethoxy)-propyl]guanine (HPMPG), 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]thymine (HPMPT), 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-2,6-diaminopurine (HPMPDAP) and 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-2-amino-6-cyclopropylaminopurine (HPMP-cPrDAP) and evaluated their antiviral activity against herpes simplex virus, type 1 (HSV-1), human cytomegalovirus (HCMV), and vaccinia, cowpox and ectromelia. Against HSV-1, subnanomolar EC(50) values were observed with ODE-HPMPA and ODE-HPMPC while ODE-HPMPG had intermediate antiviral activity with an EC(50) of 40 nM. In HFF cells infected with HCMV, the lowest EC(50) values were observed with ODE-HPMPC, 0.9 nM. ODE-HPMPA was highly active with an EC(50) of 3 nM, while ODE-HPMPG and ODE-HPMPDAP were also highly active with EC(50)s of 22 and 77 nM, respectively. Against vaccinia and cowpox viruses, ODE-HPMPG and ODE-HPMPDAP were the most active and selective compounds with EC(50) values of 20-60 nM and selectivity index values of 600-3500. ODE-HPMPG was also active against ectromelia virus with an EC(50) value of 410 nM and a selectivity index value of 166. ODE-HPMPG and ODE-HPMPDAP are proposed for further preclinical evaluation as possible candidates for treatment of HSV, HCMV or orthopoxvirus diseases.
我们之前的研究表明,9-(S)-[3-羟基-2-(膦酸甲氧基)丙基]腺嘌呤(HPMPA)或 1-(S)-[3-羟基-2-(膦酸甲氧基)丙基]胞嘧啶(HPMPC)与烷氧基烷基如十六烷氧基丙基(HDP)或十八烷氧基乙基(ODE)酯化,可大大提高抗病毒活性和口服生物利用度。HDP 和 ODE 酯的 HPMPA 被证明对感染人类免疫缺陷病毒 1 型(HIV-1)的细胞具有活性,而 HPMPA 本身几乎没有活性。为了更详细地研究这种方法,我们在该系列中合成了四种新化合物,即 9-(S)-[3-羟基-2-(膦酸甲氧基)丙基]鸟嘌呤(HPMPG)、1-(S)-[3-羟基-2-(膦酸甲氧基)丙基]胸腺嘧啶(HPMPT)、9-(S)-[3-羟基-2-(膦酸甲氧基)丙基]-2,6-二氨基嘌呤(HPMPDAP)和 9-(S)-[3-羟基-2-(膦酸甲氧基)丙基]-2-氨基-6-环丙基氨基嘌呤(HPMP-cPrDAP),并评估了它们对单纯疱疹病毒 1 型(HSV-1)、人巨细胞病毒(HCMV)和牛痘、牛痘和痘苗的抗病毒活性。对于 HSV-1,ODE-HPMPA 和 ODE-HPMPC 的 EC(50)值为纳摩尔级,而 ODE-HPMPG 的抗病毒活性则处于中间水平,EC(50)值为 40 nM。在感染 HCMV 的 HFF 细胞中,观察到 ODE-HPMPC 的最低 EC(50)值为 0.9 nM。ODE-HPMPA 具有高度的活性,EC(50)值为 3 nM,而 ODE-HPMPG 和 ODE-HPMPDAP 也具有高度的活性,EC(50)值分别为 22 和 77 nM。对于牛痘和痘苗病毒,ODE-HPMPG 和 ODE-HPMPDAP 是最具活性和选择性的化合物,EC(50)值为 20-60 nM,选择性指数值为 600-3500。ODE-HPMPG 对痘苗病毒也具有活性,EC(50)值为 410 nM,选择性指数值为 166。ODE-HPMPG 和 ODE-HPMPDAP 被提议用于进一步的临床前评估,作为治疗单纯疱疹病毒、人巨细胞病毒或正痘病毒疾病的候选药物。